Early and Stable Mouse Model of Amphotericin B‐Induced Acute Kidney Injury: Application of Continuous Non‐Invasive GFR Monitoring

Authors:

Abstract
Background: Amphotericin B (AmB) remains a cornerstone in antifungal therapy, but its clinical use is limited by dose‐dependent nephrotoxicity. Lipid‐based formulations such as amphotericin B cholesterol sulfate complex dispersion (ABCD) were developed to mitigate renal injury, though their comparative renal safety profiles remain incompletely defined.Objective: This study aimed to establish a pharmacologically relevant mouse model to characterise the nephrotoxicity of conventional AmB (AmB‐D) and ABCD formulations, using continuous non‐invasive glomerular filtration rate (GFR) monitoring and renal injury biomarkers.Methods: Male C57BL/6 mice received a single intravenous dose of AmB‐D or ABCD at low or high doses. Renal function was assessed via real‐time GFR monitoring, serum creatinine (SCr), blood urea nitrogen (BUN) and mRNA expression of kidney injury molecule‐1 (KIM‐1) and neutrophil gelatinase‐associated lipocalin (NGAL). Histopathological injury was evaluated at defined time points.Results: High‐dose AmB‐D (2 mg/kg) and ABCD (20 mg/kg) induced rapid GFR decline within 2 h, preceding significant increases in SCr, BUN, and injury biomarkers. ABCD demonstrated 6–10‐fold lower nephrotoxic potency compared to AmB‐D. Low‐dose groups exhibited mild, reversible changes in GFR and minimal tubular injury.Conclusion: Continuous GFR monitoring enables sensitive detection of early renal dysfunction and reveals distinct nephrotoxic profiles between AmB‐D and ABCD. This pharmacologically relevant model provides a powerful tool for preclinical nephrotoxicity assessment and for quantitatively comparing the renal safety of different drug formulations.
Funding Information
  • National Natural Science Foundation of China (82472198, 82430069)

This publication has 32 references indexed in Scilit: